Cellectar Biosciences INC NEW financials
$1.82−0.55%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$23.0M | -$59.5M | -$39.0M | -$28.8M | -$24.1M | -$15.3M | -$14.2M | -$13.3M | -$13.6M | -$9.4M |
| Net income | -$21.8M | -$44.6M | -$42.8M | -$31.8M | -$24.1M | -$15.1M | -$14.1M | -$15.5M | -$15.0M | -$9.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-8.35 | $-41.89 | $-105.00 | $-135.30 | $-130.50 | $-228.00 | $-552.00 | $-1569.00 | $-3210.00 | $-6420.00 |
| EBITDA | -$22.8M | -$59.2M | -$38.8M | -$28.7M | -$24.0M | -$15.1M | -$14.0M | -$11.6M | -$12.1M | -$9.1M |
| Operating cash flow | -$23.1M | -$47.6M | -$32.4M | -$25.2M | -$22.6M | -$13.9M | -$11.7M | -$11.4M | -$11.0M | -$8.3M |
| Free cash flow | -$23.1M | -$47.7M | -$33.2M | -$25.4M | -$22.7M | -$14.0M | -$11.7M | -$11.8M | -$11.4M | -$8.4M |
| Diluted shares | 2.6M | 1.2M | 0.4M | 0.2M | 0.2M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.2M | $23.3M | $9.6M | $19.9M | $35.7M | $57.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $37.2M | $58.7M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $12.1M | $4.2M | $3.9M |
| Shareholders' equity | $8.5M | $14.3M | -$15.2M | $8.2M | $33.0M | $54.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology